Skip to main content
For Healthcare Professionals

TRAJENTA DUO®

Overview

TRAJENTA DUO® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus below: (1) Patients those already being treated and well controlled with the free combination of linagliptin and metformin. (2) Patients inadequately controlled on metformin alone. (3) In combination with a sulphonylurea (i.e., triple combination therapy) in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.

Product overview

TRAJENTA DUO® combines 2 antihyperglycemic agents with complementary mechanisms of action to improve glycemic control in patients with type 2 diabetes mellitus: linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, and metformin, a member of the biguanide class.

Product key facts

product_key2

Indication

TRAJENTA DUO® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus below

  • Patients those already being treated and well controlled with the free combination of linagliptin and metformin.
  • Patients inadequately controlled on metformin alone.
  • In combination with a sulphonylurea (i.e., triple combination therapy) in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.
brand_names

Limitations of Use

  • TRAJENTA DUO® is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.
  • TRAJENTA DUO® has not been studied in patients with a history of pancreatitis, and it is unknown if using TRAJENTA DUO® would increase the risk of developing pancreatitis in these patients.
product_key3

Active ingredients

Linagliptin

Metformin Hydrochloride

product_key4

Legal category

Prescription only medicine

 

product_key6

Dosage form and drug content

2.5 mg linagliptin/850 mg metformin HCl Film-Coated tablets

product_Key7

Administration form

Oral administration

product_key1

Pack sizes

One box contains 4-1,000 tablets in PVC/PCTFE blister package.

Footnote:

  • DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; NHIA, National Health Insurance Administration; RA, receptor agonist; SGLT-2, sodium-glucose cotransporter 2.

Reference:

  1. TRAJENTA DUO® approved package insert. Updated in December 2020 and approved in February 2021.

Reporting adverse events

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.